Dr William Kuziel | Director of External Scientific Affairs
Daiichi Sankyo Group

Dr William Kuziel, Director of External Scientific Affairs, Daiichi Sankyo Group

Dr. Kuziel joined Daiichi Sankyo in 2008 and is currently a Director in the External Scientific Affairs group. He is responsible for identifying and evaluating opportunities for research collaboration, in licensing and M&A in the areas of antibody-drug conjugates, immuno-oncology, cell therapy and advanced technology platforms for the discovery, design and development of novel therapeutic biologics.
 
Dr. Kuziel received his B.S. in Biology from the Pennsylvania State University and his Ph.D. in Immunology from the University of Texas Southwestern Medical Center at Dallas.  He did post-doctoral training in Immunology at the Howard Hughes Medical Institute at the Duke University Medical Center.
 
After two years as a visiting scientist in the Department of Pathology and Laboratory Medicine at the University of North Carolina Medical Center at Chapel Hill, Dr. Kuziel joined the Department of Molecular Genetics and Microbiology at the University of Texas at Austin as an Assistant Professor.  His research focused on making and using novel knockout mouse strains to study the molecular and cellular basis of inflammatory disease processes.  He also designed and taught undergraduate courses in Immunology and Infectious Disease.  In his research career he has published 120 peer-reviewed scientific publications.
 
Dr. Kuziel began his career in drug development in 2004 at Protein Design Labs where he established and led a research group to validate novel therapeutic targets and test monoclonal antibody drug candidates in a variety of inflammatory disease models.  He also served on several therapeutic monoclonal antibody clinical development and life cycle management teams.

Appearances:



Agenda Day 1 @ 2:45

Corporate Venture Panel: Unique investment strategies and investing in platform technologies

  • What are corporate venture firms looking for? What is the best point of entry?
  • What is the nature of the terms and conditions; the unique structure of each CVC firm
  • How closely do we work with our parent companies?
  • Investing in early-stage companies and investment timelines
  • Differences in balance between strategic focus and financial focus.

back to speakers